Cereno Scientific

Cereno Scientific AB is a clinical-stage biotechnology company headquartered in Gothenburg, Sweden, with a US subsidiary in Boston, Massachusetts. The company, listed on the Nasdaq First North, is focused on developing therapies for rare cardiovascular and pulmonary diseases. The business model is centered on addressing unmet medical needs in niche markets, which can allow for shorter development timelines and potentially faster market entry. Cereno's strategy involves advancing its drug candidates through clinical proof-of-concept and then pursuing commercialization through potential partnerships and licensing agreements.

The company's vision originated with Professor Sarker Jaen from Gothenburg, who aimed to develop a drug to prevent thrombosis without the high risk of bleeding associated with existing treatments. Sten R. Sörensen, who has a background in chemistry and extensive experience from senior roles at major pharmaceutical companies like AstraZeneca and Monsanto, joined Cereno's board in 2014 and became CEO in 2015. His previous work includes initiating landmark survival studies for heart failure treatments. Dr. Björn Dahlöf, the Chief Scientific Officer, has been with Cereno since 2012 and brings over 35 years of clinical experience in cardiovascular research, drug development, and clinical trials. He is an associate professor at Sahlgrenska University Hospital and has authored over 400 scientific publications.

Cereno Scientific's pipeline is built around epigenetic modulation, specifically through histone deacetylase (HDAC) inhibition, to address the root causes of diseases rather than just managing symptoms. The lead candidate, CS1, is a formulation of valproic acid being developed as a disease-modifying oral therapy for Pulmonary Arterial Hypertension (PAH). A Phase IIa trial demonstrated that CS1 was safe and showed a positive impact on exploratory clinical efficacy parameters. The company's second asset, CS014, is a new chemical entity also based on HDAC inhibition, targeting Idiopathic Pulmonary Fibrosis (IPF) and is currently in Phase I development. A third program, CS585, is a preclinical, oral prostacyclin (IP) receptor agonist showing potential for thrombosis prevention without increased bleeding risk.

Keywords: Cereno Scientific, biotechnology, cardiovascular diseases, pulmonary diseases, rare diseases, epigenetic modulation, HDAC inhibitors, CS1, Pulmonary Arterial Hypertension (PAH), CS014, Idiopathic Pulmonary Fibrosis (IPF), CS585, thrombosis prevention, clinical-stage, drug development, Sten R Sörensen, Björn Dahlöf, Gothenburg, Nasdaq First North, disease-modifying therapy, valproic acid, prostacyclin receptor agonist